In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Abramson Cancer Center, Perelman School of Medicine University of Pennsylvania
Answered on
The management of MCL for almost 2 decades was driven by extrapolated data from aggressive B-cell lymphoma. However, aggressive chemotherapy and stem cell transplantation have failed to produce a plateau on overall survival curves, and patients inevitably have relapsed. It is now clear that MCL, par...
Join for free or sign in to see the full answer